Graham K Johnson

US Patent:

20210363155, Nov 25, 2021

Filed:

May 13, 2021

Appl. No.:

17/320158

Inventors:

- New York NY, US
Christopher Cioffi - Troy NY, US
Graham Johnson - Sanbornton NH, US
Nicoleta Dobri - New York NY, US
Emily Freeman - Voorheesville NY, US
Ping Chen - Slingerlands NY, US
Michael Conlon - Schenectady NY, US
Lei Zhu - Glenmont NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07D 498/04
C07D 471/04
C07D 487/04
C07D 495/04
A61P 27/02
A61K 31/501
A61K 31/437
A61K 31/4545
A61K 31/5025
A61K 31/506
A61K 31/4375
A61K 31/454
A61K 31/497
C07D 401/06
C07D 405/14
C07D 409/06
C07D 491/052

Abstract:

The present invention provides a compound having the structure:

US Patent:

20210214360, Jul 15, 2021

Filed:

Nov 16, 2020

Appl. No.:

17/099231

Inventors:

- New York NY, US
Christopher Cioffi - Troy NY, US
Graham Johnson - Sanbornton NH, US
Rando Allikmets - Cornwall on Hudson NY, US
Emily Freeman - Voorheesville NY, US
Ping Chen - Slingerlands NY, US
Michael Conlon - Schenectady NY, US
Lei Zhu - Glenmont NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07D 487/04
C07D 471/04

Abstract:

The present invention provides a compound having the structure:or a pharmaceutically acceptable salt thereof.

US Patent:

20190382409, Dec 19, 2019

Filed:

Jul 24, 2019

Appl. No.:

16/520886

Inventors:

- New York NY, US
Christopher Cioffi - Troy NY, US
Graham Johnson - Sanbornton NH, US
Rando Allikmets - Cornwall on Hudson NY, US
Emily Freeman - Voorheesville NY, US
Ping Chen - Slingerlands NY, US
Michael Conlon - Schenectady NY, US
Lei Zhu - Glenmont NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07D 487/04
C07D 471/04

Abstract:

The present invention provides a compound having the structure:or a pharmaceutically acceptable salt thereof.

US Patent:

20190031681, Jan 31, 2019

Filed:

Oct 3, 2018

Appl. No.:

16/151019

Inventors:

- New York NY, US
Christopher Cioffi - Troy NY, US
Graham Johnson - Sanbornton NH, US
Nicoleta Dobri - New York NY, US
Emily Freeman - Voorheesville NY, US
Ping Chen - Slingerlands NY, US
Michael Conlon - Schenectady NY, US
Lei Zhu - Glenmont NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07D 498/04
C07D 471/04
C07D 491/052
C07D 409/06
C07D 405/14
C07D 401/06
C07D 487/04
C07D 495/04

Abstract:

The present invention provide a compound having the structure: (structurally represented) wherein R, R, R, R, and Rare each independently H, halogen, CFor C-Calkyl; Ris H, OH, or halogen; B is a substituted or unsubstituted heterobicycle, pyridazine, pyrazole, pyrazine, thiadiazole, or triazole, wherein the heterocycle is other than chloro substituted indole; and the pyrazole, when substituted, is substituted with other than trifluoromethyl, or a pharmaceutically acceptable salt thereof.

US Patent:

20180237391, Aug 23, 2018

Filed:

Mar 26, 2018

Appl. No.:

15/935918

Inventors:

- New York NY, US
Christopher Cioffi - Albany NY, US
Graham Johnson - Sanbornton NH, US
Nicoleta Dobri - New York NY, US
Emily Freeman - Albany NY, US
Ping Chen - Albany NY, US
Michael Conlon - Albany NY, US
Lei Zhu - Albany NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07D 209/52
C07D 498/04
C07D 487/04
C07D 471/04
C07D 401/04
C07D 403/06
C07D 403/04
C07D 401/12
C07D 403/12

Abstract:

The present invention provides Octahydrocyclopentapyrrole compounds having the structure: (structurally represented) wherein psi is absent or present, and when present is a bond; R1, R2, R3, R4, and R5 are each independently H, halogen, CF, or C1-C4 alkyl; R6 is absent or present, and when present is H, OH, or halogen; A is absent or present, and when present is C(O) or C(O)NH; B is substituted or unsubstituted monocycle, bicycle, heteromonocycle, heterobicycle, benzyl, CO2H or (C1-C4 alkyl)-CO2H, wherein when B is CO2H, then A is present and is C(O); and when psi is present, then R6 is absent and when psi is absent, then R6 is present, or a pharmaceutically acceptable salt thereof, for treatment of diseases characterized by excessive lipofuscin accumulation in the retina.